April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
April 2012 Drug Information Update - Pharmacy Benefits ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
750 mg tablets, 100 count (NDC 10135-0468-01)<br />
Reason for the Shortage<br />
• Caraco has discontinued their product. Product was recently seized by US Marshals due to good<br />
manufacturing practice violations (see news release for more information).<br />
• Marlex could not provide a reason for their shortage.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=556<br />
Source: www.ashp.org<br />
Oxycodone Immediate Release Tablets and Capsules<br />
March 16, <strong>2012</strong><br />
Products Affected - Description<br />
Immediate Release Tablets<br />
Oxycodone Immediate-Release Tablets, Qualitest<br />
5 mg tablets, 100 count (NDC 00603-4990-21)<br />
5 mg tablets, 500 count (NDC 00603-4990-28)<br />
15 mg tablets, 100 count (NDC 00603-4991-21)<br />
15 mg tablets, 500 count (NDC 00603-4991-28)<br />
30 mg tablets, 100 count (NDC 00603-4992-21)<br />
30 mg tablets, 500 count (NDC 00603-4992-28)<br />
Oxycodone Immediate-Release Tablets, Caraco<br />
15 mg tablets, 100 count (NDC 57664-0187-88)<br />
30 mg tablets, 100 count (NDC 57664-0224-88)<br />
Immediate Release Capsules<br />
Oxycodone Immediate-Release Capsules, Mallinckrodt<br />
5 mg capsules, 100 count (NDC 00406-0554-01) - discontinued<br />
Oxycodone Immediate-Release Capsules, MidLothian Labs<br />
5 mg, 100 count (NDC 68308-0145-10) - discontinued<br />
Reason for the Shortage<br />
• Caraco, Mallinckrodt, Qualitest, and Xanodyne could not provide a reason for the shortage.<br />
• Mallinckrodt discontinued their oxycodone immediate-release 5 mg capsules in May, 2011.<br />
Article link: http://www.ashp.org/<strong>Drug</strong>Shortages/Current/Bulletin.aspx?id=509<br />
Source: www.ashp.org<br />
Vinblastine Injection<br />
March 20, <strong>2012</strong><br />
Products Affected - Description<br />
Vinblastine lyophilized powder for injection, Bedford<br />
10 mg vial (NDC 55390-0091-10)<br />
Vinblastine sulfate injection, APP<br />
1 mg/mL, 10 mL vial (NDC 63323-0278-10)<br />
Reason for the Shortage<br />
• Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011.<br />
Product will become available in stages as production resumes.<br />
• Bedford Laboratories has multiple products affected by this suspension of manufacturing.<br />
Availability of all products, including those not manufactured at Ben Venue, is updated as<br />
information changes on the Bedford Laboratories website.<br />
• APP has their product in short supply due to increased demand for the product and a<br />
manufacturing delay.<br />
47
Change language